Alexander J. Lenvik

1.2k total citations
15 papers, 937 citations indexed

About

Alexander J. Lenvik is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Alexander J. Lenvik has authored 15 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 10 papers in Oncology and 1 paper in Hematology. Recurrent topics in Alexander J. Lenvik's work include Immune Cell Function and Interaction (14 papers), CAR-T cell therapy research (9 papers) and T-cell and B-cell Immunology (5 papers). Alexander J. Lenvik is often cited by papers focused on Immune Cell Function and Interaction (14 papers), CAR-T cell therapy research (9 papers) and T-cell and B-cell Immunology (5 papers). Alexander J. Lenvik collaborates with scholars based in United States, Sweden and Germany. Alexander J. Lenvik's co-authors include Jeffrey S. Miller, Martin Felices, Bruce R. Blazar, Daniel A. Vallera, Ron McElmurry, Jakub Tolar, Michael R. Verneris, Daniel J. Weisdorf, Laura E. Bendzick and Melissa A. Geller and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Alexander J. Lenvik

12 papers receiving 918 citations

Peers

Alexander J. Lenvik
Michelle Gleason United States
Peter Hinderlie United States
Joerg Uwe Schmohl Germany
Cécile Bonnafous France
Tsin Yee Tai Australia
Katja Klausz Germany
Hilde Omholt Norway
Huaijian Guo Canada
Dawn K. Schirm United States
Elizabeth Taras United States
Michelle Gleason United States
Alexander J. Lenvik
Citations per year, relative to Alexander J. Lenvik Alexander J. Lenvik (= 1×) peers Michelle Gleason

Countries citing papers authored by Alexander J. Lenvik

Since Specialization
Citations

This map shows the geographic impact of Alexander J. Lenvik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander J. Lenvik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander J. Lenvik more than expected).

Fields of papers citing papers by Alexander J. Lenvik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander J. Lenvik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander J. Lenvik. The network helps show where Alexander J. Lenvik may publish in the future.

Co-authorship network of co-authors of Alexander J. Lenvik

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander J. Lenvik. A scholar is included among the top collaborators of Alexander J. Lenvik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander J. Lenvik. Alexander J. Lenvik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Kumar, Akhilesh, Alexander J. Lenvik, Martin Felices, et al.. (2025). The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity. The Journal of Immunology. 214(11). 2961–2975.
3.
Zorko, Nicholas A., Martin Felices, Aimee Merino, et al.. (2021). 126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies. Annals of Oncology. 32. S1433–S1433. 4 indexed citations
4.
Felices, Martin, Todd Lenvik, Behiye Kodal, et al.. (2020). Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunology Research. 8(9). 1139–1149. 51 indexed citations
5.
Miller, Jeffrey S., Nicholas A. Zorko, Behiye Kodal, et al.. (2020). 470 Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors. SHILAP Revista de lepidopterología. A287–A288. 2 indexed citations
6.
Felices, Martin, Alexander J. Lenvik, Ron McElmurry, et al.. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 3(3). 184 indexed citations
7.
Felices, Martin, Craig E. Eckfeldt, Todd Lenvik, et al.. (2017). Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models. Blood. 130. 4465–4465. 1 indexed citations
8.
Felices, Martin, Alexander J. Lenvik, Aaron M. LeBeau, et al.. (2017). Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Research and Treatment. 49(4). 1140–1152. 74 indexed citations
9.
Felices, Martin, Sami Chu, Behiye Kodal, et al.. (2017). IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecologic Oncology. 145(3). 453–461. 103 indexed citations
10.
Geller, Melissa A., Caitlin Ryan, Alexander J. Lenvik, et al.. (2017). Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer. Gynecologic Oncology. 145. 19–19. 2 indexed citations
11.
Vallera, Daniel A., Martin Felices, Ron McElmurry, et al.. (2016). IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clinical Cancer Research. 22(14). 3440–3450. 295 indexed citations
12.
Felices, Martin, Alexander J. Lenvik, Sami Chu, et al.. (2016). Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity. Blood. 128(22). 551–551. 5 indexed citations
13.
Felices, Martin, Daniel A. Vallera, Ron McElmurry, et al.. (2016). CD16-IL15-CD33 Trispecific Killer Engager (TriKE) induces NK cell expansion, persistence, and myeloid blast antigen specific killing.. The Journal of Immunology. 196(1_Supplement). 75.8–75.8.
14.
15.
Gleason, Michelle, Julie A. Ross, Erica D. Warlick, et al.. (2014). CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123(19). 3016–3026. 208 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle Gleason Breakdown of academic impact, for papers by Peter Hinderlie Breakdown of academic impact, for papers by Joerg Uwe Schmohl Breakdown of academic impact, for papers by Cécile Bonnafous Breakdown of academic impact, for papers by Tsin Yee Tai Breakdown of academic impact, for papers by Katja Klausz Breakdown of academic impact, for papers by Hilde Omholt Breakdown of academic impact, for papers by Huaijian Guo Breakdown of academic impact, for papers by Dawn K. Schirm Breakdown of academic impact, for papers by Elizabeth Taras
Rankless by CCL
2026